Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (2 issues)
Up 26.55% on 8.5x volume, closing in on the 52-week high at 18.14: the first post-launch YARTEMLEA quarter delivered $32.2M gross revenue (+190% q/q) and a swing to positive adjusted net income. After a 73% month, 7-day RSI sits at 94.1; the 153.6% implied upside from 4 analysts needs another quarter of proof. No buying a 26% day. Sidelines.
Inched up 0.81%, extending a 36.3% monthly rebound with RSI now overheated at 71.8: EU regulators issued a negative opinion on its stem-cell transplant therapy while bulls bet on a re-examination win plus U.S. billing-code catalysts—a fiercely polarized fight. With just 3 covering analysts, this is speculators' turf; sidelines.